{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T08:29:28Z","timestamp":1765268968981},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00115-024-01684-8","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T09:01:54Z","timestamp":1719306114000},"page":"622-629","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmakologische Behandlung der Posttraumatischen Belastungsst\u00f6rung","Pharmacological treatment of posttraumatic stress disorder"],"prefix":"10.1007","volume":"95","author":[{"given":"Stefan","family":"Roepke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Schellong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels","family":"Bergemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Frommberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"key":"1684_CR1","unstructured":"WHO (2024) ICD-11 for mortality and morbidity statistics 6B40 post traumatic stress disorder. https:\/\/icd.who.int\/browse\/2024-01\/mms\/en#2070699808"},{"key":"1684_CR2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5.\u00a0Aufl. American Psychiatric Publishing","edition":"5"},{"issue":"1","key":"1684_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41398-019-0673-5","volume":"9","author":"A Wright","year":"2019","unstructured":"Wright A, Sijbrandij M, Sinnerton R, Lewis C, Roberts NP, Bisson JI (2019) Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysisLaurence.  Transl Psychiatry 9(1):334. https:\/\/doi.org\/10.1038\/s41398-019-0673-5","journal-title":"Transl Psychiatry"},{"issue":"3","key":"1684_CR4","doi-asserted-by":"publisher","first-page":"Cd002795","DOI":"10.1002\/14651858.CD002795.pub3","volume":"3","author":"T Williams","year":"2022","unstructured":"Williams\u00a0T, Phillips\u00a0NJ, Stein\u00a0DJ, Ipser\u00a0JC (2022) Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev 3(3):Cd2795. https:\/\/doi.org\/10.1002\/14651858.CD002795.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1684_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.4088\/jcp.v68n0105","volume":"68","author":"BA van der Kolk","year":"2007","unstructured":"van der Kolk\u00a0BA, Spinazzola\u00a0J, Blaustein\u00a0ME, Hopper\u00a0JW, Hopper\u00a0EK, Korn\u00a0DL, Simpson\u00a0WB (2007) A\u00a0randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J\u00a0Clin Psychiatry 68(1):37\u201346. https:\/\/doi.org\/10.4088\/jcp.v68n0105","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"1684_CR6","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1345\/aph.1A195","volume":"36","author":"RS Gregorian","year":"2002","unstructured":"Gregorian\u00a0RS, Golden\u00a0KA, Bahce\u00a0A, Goodman\u00a0C, Kwong\u00a0WJ, Khan\u00a0ZM (2002) Antidepressant-induced sexual dysfunction. Ann Pharmacother 36(10):1577\u20131589. https:\/\/doi.org\/10.1345\/aph.1A195","journal-title":"Ann Pharmacother"},{"issue":"12","key":"1684_CR7","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.2174\/1389450117666161227142947","volume":"19","author":"NAM Rappek","year":"2018","unstructured":"Rappek\u00a0NAM, Sidi\u00a0H, Kumar\u00a0J, Kamarazaman\u00a0S, Das\u00a0S, Masiran\u00a0R, Baharuddin\u00a0N, Hatta\u00a0MH (2018) Serotonin selective reuptake inhibitors (SSRis) and female sexual dysfunction (FSD): hypothesis on its association and options of treatment. Curr Drug Targets 19(12):1352\u20131358. https:\/\/doi.org\/10.2174\/1389450117666161227142947","journal-title":"Curr Drug Targets"},{"issue":"10","key":"1684_CR8","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1001\/archpsyc.63.10.1158","volume":"63","author":"J Davidson","year":"2006","unstructured":"Davidson\u00a0J, Baldwin\u00a0D, Stein\u00a0DJ, Kuper\u00a0E, Benattia\u00a0I, Ahmed\u00a0S, Pedersen\u00a0R, Musgnung\u00a0J (2006) Treatment of posttraumatic stress disorder with venlafaxine extended release: a\u00a06-month randomized controlled trial. Arch Gen Psychiatry 63(10):1158\u20131165. https:\/\/doi.org\/10.1001\/archpsyc.63.10.1158","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"1684_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/01.jcp.0000222514.71390.c1","volume":"26","author":"J Davidson","year":"2006","unstructured":"Davidson\u00a0J, Rothbaum\u00a0BO, Tucker\u00a0P, Asnis\u00a0G, Benattia\u00a0I, Musgnung\u00a0JJ (2006) Venlafaxine extended release in posttraumatic stress disorder: a\u00a0sertraline- and placebo-controlled study. J\u00a0Clin Psychopharmacol 26(3):259\u2013267. https:\/\/doi.org\/10.1097\/01.jcp.0000222514.71390.c1","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1684_CR10","doi-asserted-by":"publisher","first-page":"1802920","DOI":"10.1080\/20008198.2020.1802920","volume":"12","author":"MD Hoskins","year":"2021","unstructured":"Hoskins\u00a0MD, Bridges\u00a0J, Sinnerton\u00a0R, Nakamura\u00a0A, Underwood\u00a0JFG, Slater\u00a0A, Lee\u00a0MRD, Clarke\u00a0L, Lewis\u00a0C, Roberts\u00a0NP, Bisson\u00a0JI (2021) Pharmacological therapy for post-traumatic stress disorder: a\u00a0systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol 12(1):1802920. https:\/\/doi.org\/10.1080\/20008198.2020.1802920","journal-title":"Eur J Psychotraumatol"},{"issue":"2","key":"1684_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/s0006-3223(02)01411-7","volume":"53","author":"JR Davidson","year":"2003","unstructured":"Davidson\u00a0JR, Weisler\u00a0RH, Butterfield\u00a0MI, Casat\u00a0CD, Connor\u00a0KM, Barnett\u00a0S, van Meter\u00a0S (2003) Mirtazapine vs. placebo in posttraumatic stress disorder: a\u00a0pilot trial. Biol Psychiatry 53(2):188\u2013191. https:\/\/doi.org\/10.1016\/s0006-3223(02)01411-7","journal-title":"Biol Psychiatry"},{"key":"1684_CR12","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13267","author":"LL Davis","year":"2020","unstructured":"Davis\u00a0LL, Pilkinton\u00a0P, Lin\u00a0C, Parker\u00a0P, Estes\u00a0S, Bartolucci\u00a0A (2020) A\u00a0randomized, placebo-controlled trial of mirtazapine for the treatment of posttraumatic stress disorder in veterans. J\u00a0Clin Psychiatry. https:\/\/doi.org\/10.4088\/JCP.20m13267","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1684_CR13","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archpsyc.1990.01810150059010","volume":"47","author":"J Davidson","year":"1990","unstructured":"Davidson\u00a0J, Kudler\u00a0H, Smith\u00a0R, Mahorney\u00a0SL, Lipper\u00a0S, Hammett\u00a0E, Saunders\u00a0WB, Cavenar\u00a0JO Jr. (1990) Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 47(3):259\u2013266. https:\/\/doi.org\/10.1001\/archpsyc.1990.01810150059010","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"1684_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/00005053-199106000-00011","volume":"179","author":"TR Kosten","year":"1991","unstructured":"Kosten\u00a0TR, Frank\u00a0JB, Dan\u00a0E, McDougle\u00a0CJ, Giller\u00a0EL Jr. (1991) Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J\u00a0Nerv Ment Dis 179(6):366\u2013370. https:\/\/doi.org\/10.1097\/00005053-199106000-00011","journal-title":"J Nerv Ment Dis"},{"issue":"12","key":"1684_CR15","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1017\/s003329171700349x","volume":"48","author":"A Cipriani","year":"2018","unstructured":"Cipriani\u00a0A, Williams\u00a0T, Nikolakopoulou\u00a0A, Salanti\u00a0G, Chaimani\u00a0A, Ipser\u00a0J, Cowen\u00a0PJ, Geddes\u00a0JR, Stein\u00a0DJ (2018) Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a\u00a0network meta-analysis. Psychol Med 48(12):1975\u20131984. https:\/\/doi.org\/10.1017\/s003329171700349x","journal-title":"Psychol Med"},{"issue":"2","key":"1684_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/JCP.0000000000001363","volume":"41","author":"BW Dunlop","year":"2021","unstructured":"Dunlop BW, Rakofsky JJ, Newport DJ, Mletzko-Crowe T, Barone K, Nemeroff CB, Harvey PD (2021) Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol 41(2):172\u2013179. https:\/\/doi.org\/10.1097\/JCP.0000000000001363","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1684_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/pra.0000000000000091","volume":"21","author":"J Guina","year":"2015","unstructured":"Guina\u00a0J, Rossetter\u00a0SR et\u00a0al (2015) Benzodiazepines for PTSD: a\u00a0systematic review and meta-analysis. J\u00a0Psychiatr Pract 21(4):281\u2013303. https:\/\/doi.org\/10.1097\/pra.0000000000000091","journal-title":"J Psychiatr Pract"},{"issue":"4","key":"1684_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1001\/jama.2020.22106","volume":"325","author":"ME Hirschtritt","year":"2021","unstructured":"Hirschtritt\u00a0ME, Olfson\u00a0M, Kroenke\u00a0K (2021) Balancing the risks and benefits of benzodiazepines. JAMA 325(4):347\u2013348. https:\/\/doi.org\/10.1001\/jama.2020.22106","journal-title":"JAMA"},{"issue":"6","key":"1684_CR19","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1016\/j.addbeh.2013.01.027","volume":"38","author":"SE Ullman","year":"2013","unstructured":"Ullman\u00a0SE, Relyea\u00a0M, Peter-Hagene\u00a0L, Vasquez\u00a0AL (2013) Trauma histories, substance use coping, PTSD, and problem substance use among sexual assault victims. Addict Behav 38(6):2219\u20132223. https:\/\/doi.org\/10.1016\/j.addbeh.2013.01.027","journal-title":"Addict Behav"},{"issue":"4","key":"1684_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000362243","volume":"69","author":"M Ahmadpanah","year":"2014","unstructured":"Ahmadpanah\u00a0M, Sabzeiee\u00a0P, Hosseini\u00a0SM, Torabian\u00a0S, Haghighi\u00a0M, Jahangard\u00a0L, Bajoghli\u00a0H, Holsboer-Trachsler\u00a0E, Brand\u00a0S (2014) Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder. Neuropsychobiology 69(4):235\u2013242. https:\/\/doi.org\/10.1159\/000362243","journal-title":"Neuropsychobiology"},{"key":"1684_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.3389\/fphar.2020.00559","volume":"11","author":"ZD Huang","year":"2020","unstructured":"Huang\u00a0ZD, Zhao\u00a0YF, Li\u00a0S, Gu\u00a0HY, Lin\u00a0LL, Yang\u00a0ZY, Niu\u00a0YM, Zhang\u00a0C, Luo\u00a0J (2020) Comparative efficacy and acceptability of pharmaceutical management for adults with post-traumatic stress disorder: a\u00a0systematic review and meta-analysis. Front Pharmacol 11:559. https:\/\/doi.org\/10.3389\/fphar.2020.00559","journal-title":"Front Pharmacol"},{"issue":"6","key":"1684_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","volume":"71","author":"A Feder","year":"2014","unstructured":"Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB, Iosifescu D, Charney DS (2014) Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 71(6):681\u2013688. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.62","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"1684_CR23","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","volume":"178","author":"A Feder","year":"2021","unstructured":"Feder\u00a0A, Costi\u00a0S, Rutter\u00a0SB, Collins\u00a0AB, Govindarajulu\u00a0U, Jha\u00a0MK, Horn\u00a0SR, Kautz\u00a0M, Corniquel\u00a0M, Collins\u00a0KA, Bevilacqua\u00a0L, Glasgow\u00a0AM, Brallier\u00a0J, Pietrzak\u00a0RH, Murrough\u00a0JW, Charney\u00a0DS (2021) A\u00a0randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Am J Psychiatry 178(2):193\u2013202. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20050596","journal-title":"Am J Psychiatry"},{"issue":"8","key":"1684_CR24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/s41386-022-01266-9","volume":"47","author":"CG Abdallah","year":"2022","unstructured":"Abdallah\u00a0CG, Roache\u00a0JD, Gueorguieva\u00a0R, Averill\u00a0LA, Young-McCaughan\u00a0S, Shiroma\u00a0PR, Purohit\u00a0P, Brundige\u00a0A, Murff\u00a0W, Ahn\u00a0KH, Sherif\u00a0MA, Baltutis\u00a0EJ, Ranganathan\u00a0M, D\u2019Souza\u00a0D, Martini\u00a0B, Southwick\u00a0SM, Petrakis\u00a0IL, Burson\u00a0RR, Guthmiller\u00a0KB et\u00a0al (2022) Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a\u00a0double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacology 47(8):1574\u20131581. https:\/\/doi.org\/10.1038\/s41386-022-01266-9","journal-title":"Neuropsychopharmacology"},{"key":"1684_CR25","doi-asserted-by":"publisher","first-page":"247054702098167","DOI":"10.1177\/2470547020981670","volume":"4","author":"AR Dadabayev","year":"2020","unstructured":"Dadabayev\u00a0AR, Joshi\u00a0SA, Reda\u00a0MH, Lake\u00a0T, Hausman\u00a0MS, Domino\u00a0E, Liberzon\u00a0I (2020) Low dose ketamine infusion for comorbid posttraumatic stress disorder and chronic pain: a\u00a0randomized double-blind clinical trial. Chronic Stress 4:2470547020981670. https:\/\/doi.org\/10.1177\/2470547020981670","journal-title":"Chronic Stress"},{"issue":"1","key":"1684_CR26","doi-asserted-by":"publisher","first-page":"2299124","DOI":"10.1080\/20008066.2023.2299124","volume":"15","author":"NC Borgogna","year":"2024","unstructured":"Borgogna\u00a0NC, Owen\u00a0T, Vaughn\u00a0J, Johnson\u00a0DAL, Aita\u00a0SL, Hill\u00a0BD (2024) So how special is special K? A\u00a0systematic review and meta-analysis of ketamine for PTSD RCTs. Eur J Psychotraumatol 15(1):2299124. https:\/\/doi.org\/10.1080\/20008066.2023.2299124","journal-title":"Eur J Psychotraumatol"},{"issue":"2","key":"1684_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.9740\/mhc.2018.03.086","volume":"8","author":"I Shishko","year":"2018","unstructured":"Shishko I, Oliveira R, Moore TA, Almeida K (2018) A review of medical marijuana for the treatment of posttraumatic stress disorder: Real symptom re-leaf or just high hopes? Ment Health Clin 8(2):86\u201394. https:\/\/doi.org\/10.9740\/mhc.2018.03.086 (eCollection 2018 Mar)","journal-title":"Clin"},{"issue":"3","key":"1684_CR28","doi-asserted-by":"publisher","first-page":"e0246990","DOI":"10.1371\/journal.pone.0246990","volume":"16","author":"MO Bonn-Miller","year":"2021","unstructured":"Bonn-Miller\u00a0MO, Sisley\u00a0S, Riggs\u00a0P, Yazar-Klosinski\u00a0B, Wang\u00a0JB, Loflin\u00a0MJE, Shechet\u00a0B, Hennigan\u00a0C, Matthews\u00a0R, Emerson\u00a0A, Doblin\u00a0R (2021) The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: a\u00a0randomized cross-over clinical trial. PLoS ONE 16(3):e246990. https:\/\/doi.org\/10.1371\/journal.pone.0246990","journal-title":"PLoS ONE"},{"issue":"7","key":"1684_CR29","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2165\/00023210-200620070-00003","volume":"20","author":"MJ Maher","year":"2006","unstructured":"Maher\u00a0MJ, Rego\u00a0SA, Asnis\u00a0GM (2006) Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 20(7):567\u2013590. https:\/\/doi.org\/10.2165\/00023210-200620070-00003","journal-title":"CNS Drugs"},{"issue":"4","key":"1684_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1017\/s0033291702005469","volume":"32","author":"JR Davidson","year":"2002","unstructured":"Davidson\u00a0JR, Landerman\u00a0LR, Farfel\u00a0GM, Clary\u00a0CM (2002) Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med 32(4):661\u2013670. https:\/\/doi.org\/10.1017\/s0033291702005469","journal-title":"Psychol Med"},{"issue":"2","key":"1684_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/hrp\/7.2.69","volume":"7","author":"PS Masand","year":"1999","unstructured":"Masand\u00a0PS, Gupta\u00a0S (1999) Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 7(2):69\u201384","journal-title":"Harv Rev Psychiatry"},{"issue":"3","key":"1684_CR32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40501-020-00222-y","volume":"7","author":"JA Brownlow","year":"2020","unstructured":"Brownlow\u00a0JA, Miller\u00a0KE, Gehrman\u00a0PR (2020) Treatment of sleep comorbidities in posttraumatic stress disorder. Curr Treat Options Psychiatry 7(3):301\u2013316. https:\/\/doi.org\/10.1007\/s40501-020-00222-y","journal-title":"Curr Treat Options Psychiatry"},{"key":"1684_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fpsyt.2020.00167","volume":"11","author":"FC Weber","year":"2020","unstructured":"Weber\u00a0FC, Norra\u00a0C, Wetter\u00a0TC (2020) Sleep disturbances and suicidality in posttraumatic stress disorder: an overview of the literature. Front Psychiatry 11:167. https:\/\/doi.org\/10.3389\/fpsyt.2020.00167","journal-title":"Front Psychiatry"},{"issue":"1","key":"1684_CR34","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1207\/s15402010bsm0401_4","volume":"4","author":"B Krakow","year":"2006","unstructured":"Krakow\u00a0B, Zadra\u00a0A (2006) Clinical management of chronic nightmares: imagery rehearsal therapy. Behav Sleep Med 4(1):45\u201370. https:\/\/doi.org\/10.1207\/s15402010bsm0401_4","journal-title":"Behav Sleep Med"},{"key":"1684_CR35","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.smrv.2019.101248","volume":"50","author":"DE Y\u00fccel","year":"2020","unstructured":"Y\u00fccel\u00a0DE, van Emmerik\u00a0AAP, Souama\u00a0C, Lancee\u00a0J (2020) Comparative efficacy of imagery rehearsal therapy and prazosin in the treatment of trauma-related nightmares in adults: a\u00a0meta-analysis of randomized controlled trials. Sleep Med Rev 50:101248. https:\/\/doi.org\/10.1016\/j.smrv.2019.101248","journal-title":"Sleep Med Rev"},{"issue":"6","key":"1684_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","volume":"378","author":"A Raskind","year":"2028","unstructured":"Raskind A, Peskind ER, Chow B, Harris C, Davis-Karim A, Holmes HA, Hart KL, McFall M, Mellman TA, Reist C, Romesser J, Rosenheck R, Shih M-C, tein MB, Swift R, Gleason T, Lu Y, Huang GD (2028) Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans Murray. N Engl J Med. 378(6):507\u2013517. https:\/\/doi.org\/10.1056\/NEJMoa1507598","journal-title":"Stress"},{"key":"1684_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.sleep.2019.06.010","volume":"67","author":"Y Zhang","year":"2020","unstructured":"Zhang\u00a0Y, Ren\u00a0R, Sanford\u00a0LD, Yang\u00a0L, Ni\u00a0Y, Zhou\u00a0J, Zhang\u00a0J, Wing\u00a0YK, Shi\u00a0J, Lu\u00a0L, Tang\u00a0X (2020) The effects of prazosin on sleep disturbances in post-traumatic stress disorder: a\u00a0systematic review and meta-analysis. Sleep Med 67:225\u2013231. https:\/\/doi.org\/10.1016\/j.sleep.2019.06.010","journal-title":"Sleep Med"},{"issue":"1","key":"1684_CR38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1055\/s-0042-107794","volume":"50","author":"S Roepke","year":"2017","unstructured":"Roepke\u00a0S, Danker-Hopfe\u00a0H, Repantis\u00a0D, Behnia\u00a0B, Bernard\u00a0F, Hansen\u00a0ML, Otte\u00a0C (2017) Doxazosin, an alpha-1-adrenergic-receptor antagonist, for nightmares in patients with posttraumatic stress disorder and\/or borderline personality disorder: a\u00a0chart review. Pharmacopsychiatry 50(1):26\u201331. https:\/\/doi.org\/10.1055\/s-0042-107794","journal-title":"Pharmacopsychiatry"},{"issue":"5","key":"1684_CR39","doi-asserted-by":"publisher","first-page":"e561","DOI":"10.4088\/JCP.14m09681.Doxazosin","volume":"77","author":"C Rodgman","year":"2016","unstructured":"Rodgman C, Verrico CD, Holst M, Thompson-Lake D, Haile CN, Garza 2nd RDL, Raskind MA, Newton TF (2016) Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial. J Clin Psychiatry. 77(5):e561\u2013e565. https:\/\/doi.org\/10.4088\/JCP.14m09681.Doxazosin","journal-title":"J Clin Psychiatry"},{"key":"1684_CR40","doi-asserted-by":"publisher","unstructured":"Back SE, Flanagan JC, Mintz J, Brady KT, Jones J, Jarnecke AM, Joseph JE, Shirley DW, Malcolm RJ, Hamner M, Litz BT, Niles BL, Young-McCaughan S, Keane TM, Peterson AL (2023) A double-blind randomized controlled trial of doxazosin for co-occurring PTSD and alcohol use disorder in veterans. J Clin Psychiatry. 84(2):21m14367. https:\/\/doi.org\/10.4088\/JCP.21m14367","DOI":"10.4088\/JCP.21m14367"},{"issue":"7","key":"1684_CR41","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40263-022-00929-x","volume":"36","author":"C Geldenhuys","year":"2022","unstructured":"Geldenhuys\u00a0C, van den Heuvel\u00a0LL, Steyn\u00a0P, Seedat\u00a0S (2022) Pharmacological management of nightmares associated with posttraumatic stress disorder. CNS Drugs 36(7):721\u2013737. https:\/\/doi.org\/10.1007\/s40263-022-00929-x","journal-title":"CNS Drugs"},{"key":"1684_CR42","unstructured":"BfArM (2023) Rote-Hand-Brief zu Topiramat: Neue Beschr\u00e4nkungen zur Verhinderung einer Exposition w\u00e4hrend der Schwangerschaft. https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2023\/rhb-topiramat.html"},{"issue":"8","key":"1684_CR43","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","volume":"34","author":"P Roitman","year":"2014","unstructured":"Roitman\u00a0P, Mechoulam\u00a0R, Cooper-Kazaz\u00a0R, Shalev\u00a0A (2014) Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig 34(8):587\u2013591. https:\/\/doi.org\/10.1007\/s40261-014-0212-3","journal-title":"Clin Drug Investig"},{"key":"1684_CR44","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.psyneuen.2014.11.002","volume":"51","author":"R Jetly","year":"2015","unstructured":"Jetly\u00a0R, Heber\u00a0A, Fraser\u00a0G, Boisvert\u00a0D (2015) The efficacy of nabilone, a\u00a0synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a\u00a0preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585\u2013588. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.11.002","journal-title":"Psychoneuroendocrinology"},{"key":"1684_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20010777","author":"M Skeie-Larsen","year":"2022","unstructured":"Skeie-Larsen\u00a0M, Stave\u00a0R, Gr\u00f8nli\u00a0J, Bjorvatn\u00a0B, Wilhelmsen-Langeland\u00a0A, Zandi\u00a0A, Pallesen\u00a0S (2022) The effects of pharmacological treatment of nightmares: a\u00a0systematic literature review and meta-analysis of placebo-controlled, randomized clinical trials. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph20010777","journal-title":"Int J Environ Res Public Health"},{"issue":"6","key":"1684_CR46","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/14656566.2019.1574745","volume":"20","author":"M Akinnusi","year":"2019","unstructured":"Akinnusi\u00a0M, El Solh\u00a0AA (2019) Drug treatment strategies for insomnia in patients with post-traumatic stress disorder. Expert Opin Pharmacother 20(6):691\u2013699. https:\/\/doi.org\/10.1080\/14656566.2019.1574745","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"1684_CR47","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1017\/s1092852900024020","volume":"14","author":"SM Stahl","year":"2009","unstructured":"Stahl\u00a0SM (2009) Mechanism of action of trazodone: a\u00a0multifunctional drug. CNS spectr 14(10):536\u2013546. https:\/\/doi.org\/10.1017\/s1092852900024020","journal-title":"CNS spectr"},{"key":"1684_CR48","doi-asserted-by":"publisher","first-page":"114840","DOI":"10.1016\/j.psychres.2022.114840","volume":"317","author":"LA Bajor","year":"2022","unstructured":"Bajor\u00a0LA, Balsara\u00a0C, Osser\u00a0DN (2022) An evidence-based approach to psychopharmacology for posttraumatic stress disorder (PTSD)\u20142022 update. Psychiatry Res 317:114840. https:\/\/doi.org\/10.1016\/j.psychres.2022.114840","journal-title":"Psychiatry Res"},{"issue":"11","key":"1684_CR49","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/sleep\/30.11.1555","volume":"30","author":"T Roth","year":"2007","unstructured":"Roth\u00a0T, Rogowski\u00a0R, Hull\u00a0S, Schwartz\u00a0H, Koshorek\u00a0G, Corser\u00a0B, Seiden\u00a0D, Lankford\u00a0A (2007) Efficacy and safety of doxepin 1\u202fmg, 3\u202fmg, and 6\u202fmg in adults with primary insomnia. Sleep 30(11):1555\u20131561. https:\/\/doi.org\/10.1093\/sleep\/30.11.1555","journal-title":"Sleep"},{"issue":"5","key":"1684_CR50","doi-asserted-by":"publisher","first-page":"901","DOI":"10.5664\/jcsm.7142","volume":"14","author":"K Gandotra","year":"2018","unstructured":"Gandotra\u00a0K, Chen\u00a0P, Jaskiw\u00a0GE, Konicki\u00a0PE, Strohl\u00a0KP (2018) Effective treatment of insomnia with mirtazapine attenuates concomitant suicidal ideation. J\u00a0Clin Sleep Med 14(5):901\u2013902. https:\/\/doi.org\/10.5664\/jcsm.7142","journal-title":"J Clin Sleep Med"},{"issue":"7","key":"1684_CR51","doi-asserted-by":"publisher","first-page":"892","DOI":"10.4088\/JCP.09m05607gry","volume":"72","author":"MH Pollack","year":"2011","unstructured":"Pollack\u00a0MH, Hoge\u00a0EA, Worthington\u00a0JJ, Moshier\u00a0SJ, Wechsler\u00a0RS, Brandes\u00a0M, Simon\u00a0NM (2011) Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a\u00a0randomized, double-blind, placebo-controlled trial. J\u00a0Clin Psychiatry 72(7):892\u2013897. https:\/\/doi.org\/10.4088\/JCP.09m05607gry","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1684_CR52","doi-asserted-by":"publisher","first-page":"21","DOI":"10.5498\/wjp.v10.i3.21","volume":"10","author":"SM Dowd","year":"2020","unstructured":"Dowd\u00a0SM, Zalta\u00a0AK, Burgess\u00a0HJ, Adkins\u00a0EC, Valdespino-Hayden\u00a0Z, Pollack\u00a0MH (2020) Double-blind randomized controlled study of the efficacy, safety and tolerability of eszopiclone vs placebo for the treatment of patients with post-traumatic stress disorder and insomnia. World J Psychiatry 10(3):21\u201328. https:\/\/doi.org\/10.5498\/wjp.v10.i3.21","journal-title":"World J Psychiatry"},{"key":"1684_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsac068","author":"TA Mellman","year":"2022","unstructured":"Mellman\u00a0TA, Birku\u00a0K, Sandhu\u00a0I, Lavela\u00a0P, Kobayashi\u00a0I (2022) Evaluation of suvorexant for trauma-related insomnia. Sleep. https:\/\/doi.org\/10.1093\/sleep\/zsac068","journal-title":"Sleep"},{"issue":"1","key":"1684_CR54","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11818-016-0097-x","volume":"21","author":"D Riemann","year":"2017","unstructured":"Riemann\u00a0D, Baum\u00a0E, Cohrs\u00a0S et\u00a0al (2017) S3-Leitlinie Nicht erholsamer Schlaf\/Schlafst\u00f6rungen. Somnologie 21(1):2\u201344","journal-title":"Somnologie"},{"issue":"6","key":"1684_CR55","doi-asserted-by":"publisher","first-page":"e14035","DOI":"10.1111\/jsr.14035","volume":"32","author":"D Riemann","year":"2023","unstructured":"Riemann\u00a0D, Espie\u00a0CA, Altena\u00a0E, Arnardottir\u00a0ES, Baglioni\u00a0C, Bassetti\u00a0CLA, Bastien\u00a0C, Berzina\u00a0N, Bjorvatn\u00a0B, Dikeos\u00a0D, Dolenc Groselj\u00a0L, Ellis\u00a0JG, Garcia-Borreguero\u00a0D, Geoffroy\u00a0PA, Gjerstad\u00a0M, Gon\u00e7alves\u00a0M, Hertenstein\u00a0E, Hoedlmoser\u00a0K, Hion\u00a0T et\u00a0al (2023) The European insomnia guideline: an update on the diagnosis and treatment of insomnia 2023. J\u00a0Sleep Res 32(6):e14035. https:\/\/doi.org\/10.1111\/jsr.14035","journal-title":"J Sleep Res"},{"issue":"2","key":"1684_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/da.20176","volume":"24","author":"RD Marshall","year":"2007","unstructured":"Marshall\u00a0RD, Lewis-Fernandez\u00a0R, Blanco\u00a0C, Simpson\u00a0HB, Lin\u00a0SH, Vermes\u00a0D, Garcia\u00a0W, Schneier\u00a0F, Neria\u00a0Y, Sanchez-Lacay\u00a0A, Liebowitz\u00a0MR (2007) A\u00a0controlled trial of paroxetine for chronic PTSD, dissociation, and interpersonal problems in mostly minority adults. Depress Anxiety 24(2):77\u201384. https:\/\/doi.org\/10.1002\/da.20176","journal-title":"Depress Anxiety"},{"issue":"4","key":"1684_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/hup.395","volume":"17","author":"G Lubin","year":"2002","unstructured":"Lubin\u00a0G, Weizman\u00a0A, Shmushkevitz\u00a0M, Valevski\u00a0A (2002) Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum Psychopharmacol 17(4):181\u2013185. https:\/\/doi.org\/10.1002\/hup.395","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"1684_CR58","doi-asserted-by":"publisher","first-page":"2265184","DOI":"10.1080\/20008066.2023.2265184","volume":"14","author":"I Escamilla","year":"2023","unstructured":"Escamilla\u00a0I, Juan\u00a0N, Pe\u00f1alva\u00a0C, S\u00e1nchez-Llorens\u00a0M, Renau\u00a0J, Benito\u00a0A, Haro\u00a0G (2023) Treatment of dissociative symptoms with opioid antagonists: a\u00a0systematic review. Eur J Psychotraumatol 14(2):2265184. https:\/\/doi.org\/10.1080\/20008066.2023.2265184","journal-title":"Eur J Psychotraumatol"},{"issue":"9","key":"1684_CR59","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/da.22511","volume":"33","author":"DJ Lee","year":"2016","unstructured":"Lee\u00a0DJ, Schnitzlein\u00a0CW, Wolf\u00a0JP, Vythilingam\u00a0M, Rasmusson\u00a0AM, Hoge\u00a0CW (2016) Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety 33(9):792\u2013806. https:\/\/doi.org\/10.1002\/da.22511","journal-title":"Depress Anxiety"},{"key":"1684_CR60","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.psychres.2018.03.069","volume":"264","author":"CB Buhmann","year":"2018","unstructured":"Buhmann\u00a0CB, Nordentoft\u00a0M, Ekstroem\u00a0M, Carlsson\u00a0J, Mortensen\u00a0EL (2018) Long-term treatment effect of trauma-affected refugees with flexible cognitive behavioural therapy and antidepressants. Psychiatry Res 264:217\u2013223. https:\/\/doi.org\/10.1016\/j.psychres.2018.03.069","journal-title":"Psychiatry Res"},{"key":"1684_CR61","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jbtep.2015.01.002","volume":"48","author":"A Popiel","year":"2015","unstructured":"Popiel\u00a0A, Zawadzki\u00a0B, Prag\u0142owska\u00a0E, Teichman\u00a0Y (2015) Prolonged exposure, paroxetine and the combination in the treatment of PTSD following a\u00a0motor vehicle accident. A\u00a0randomized clinical trial\u2014the \u201eTRAKT\u201c study. J\u00a0Behav Ther Exp Psychiatry 48:17\u201326. https:\/\/doi.org\/10.1016\/j.jbtep.2015.01.002","journal-title":"J Behav Ther Exp Psychiatry"},{"issue":"2","key":"1684_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1001\/jamapsychiatry.2018.3412","volume":"76","author":"SAM Rauch","year":"2019","unstructured":"Rauch\u00a0SAM, Kim\u00a0HM, Powell\u00a0C, Tuerk\u00a0PW, Simon\u00a0NM, Acierno\u00a0R, Allard\u00a0CB, Norman\u00a0SB, Venners\u00a0MR, Rothbaum\u00a0BO, Stein\u00a0MB, Porter\u00a0K, Martis\u00a0B, King\u00a0AP, Liberzon\u00a0I, Phan\u00a0KL, Hoge\u00a0CW (2019) Efficacy of prolonged exposure therapy, sertraline hydrochloride, and their combination among combat veterans with posttraumatic stress disorder: a\u00a0randomized clinical trial. JAMA Psychiatry 76(2):117\u2013126. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3412","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"1684_CR63","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1176\/appi.ajp.2018.17090995","volume":"176","author":"LA Zoellner","year":"2019","unstructured":"Zoellner\u00a0LA, Roy-Byrne\u00a0PP, Mavissakalian\u00a0M, Feeny\u00a0NC (2019) Doubly randomized preference trial of prolonged exposure versus sertraline for treatment of PTSD. Am J Psychiatry 176(4):287\u2013296. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17090995","journal-title":"Am J Psychiatry"},{"issue":"5","key":"1684_CR64","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/jts.20170","volume":"19","author":"BO Rothbaum","year":"2006","unstructured":"Rothbaum\u00a0BO, Cahill\u00a0SP, Foa\u00a0EB, Davidson\u00a0JR, Compton\u00a0J, Connor\u00a0KM, Astin\u00a0MC, Hahn\u00a0CG (2006) Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J\u00a0Trauma Stress 19(5):625\u2013638. https:\/\/doi.org\/10.1002\/jts.20170","journal-title":"J Trauma Stress"},{"issue":"3","key":"1684_CR65","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4088\/jcp.v69n0309","volume":"69","author":"NM Simon","year":"2008","unstructured":"Simon\u00a0NM, Connor\u00a0KM, Lang\u00a0AJ, Rauch\u00a0S, Krulewicz\u00a0S, LeBeau\u00a0RT, Davidson\u00a0JR, Stein\u00a0MB, Otto\u00a0MW, Foa\u00a0EB, Pollack\u00a0MH (2008) Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. J\u00a0Clin Psychiatry 69(3):400\u2013405. https:\/\/doi.org\/10.4088\/jcp.v69n0309","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1684_CR66","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1176\/appi.ajp.2011.11020321","volume":"169","author":"FR Schneier","year":"2012","unstructured":"Schneier\u00a0FR, Neria\u00a0Y, Pavlicova\u00a0M, Hembree\u00a0E, Suh\u00a0EJ, Amsel\u00a0L, Marshall\u00a0RD (2012) Combined prolonged exposure therapy and paroxetine for PTSD related to the World Trade Center attack: a\u00a0randomized controlled trial. Am J Psychiatry 169(1):80\u201388. https:\/\/doi.org\/10.1176\/appi.ajp.2011.11020321","journal-title":"Am J Psychiatry"},{"issue":"6","key":"1684_CR67","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell\u00a0JM, Bogenschutz\u00a0M, Lilienstein\u00a0A, Harrison\u00a0C, Kleiman\u00a0S, Parker-Guilbert\u00a0K, Ot\u2019alora\u00a0GM, Garas\u00a0W, Paleos\u00a0C, Gorman\u00a0I, Nicholas\u00a0C, Mithoefer\u00a0M, Carlin\u00a0S, Poulter\u00a0B, Mithoefer\u00a0A, Quevedo\u00a0S, Wells\u00a0G, Klaire\u00a0SS, van der Kolk\u00a0B et\u00a0al (2021) MDMA-assisted therapy for severe PTSD: a\u00a0randomized, double-blind, placebo-controlled phase\u00a03\u00a0study. Nat Med 27(6):1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"issue":"3","key":"1684_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1176\/appi.focus.23021011","volume":"21","author":"JM Mitchell","year":"2023","unstructured":"Mitchell\u00a0JM, Bogenschutz\u00a0M, Lilienstein\u00a0A, Harrison\u00a0C, Kleiman\u00a0S, Parker-Guilbert\u00a0K, Ot\u2019alora\u00a0GM, Garas\u00a0W, Paleos\u00a0C, Gorman\u00a0I, Nicholas\u00a0C, Mithoefer\u00a0M, Carlin\u00a0S, Poulter\u00a0B, Mithoefer\u00a0A, Quevedo\u00a0S, Wells\u00a0G, Klaire\u00a0SS, van der Kolk\u00a0B et\u00a0al (2023) MDMA-assisted therapy for severe PTSD: a\u00a0randomized, double-blind, placebo-controlled phase\u00a03 study. FOC 21(3):315\u2013328. https:\/\/doi.org\/10.1176\/appi.focus.23021011","journal-title":"FOC"},{"key":"1684_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-59783-5","volume-title":"S3-Leitlinie posttraumatische Belastungsst\u00f6rung","author":"I Sch\u00e4fer","year":"2019","unstructured":"Sch\u00e4fer\u00a0I, Gast\u00a0U, Hofmann\u00a0A, Knaevelsrud\u00a0C, Lampe\u00a0A, Liebermann\u00a0P, Lotzin\u00a0A, Maercker\u00a0A, Rosner\u00a0R, W\u00f6ller\u00a0W (2019) S3-Leitlinie posttraumatische Belastungsst\u00f6rung. Springer, Berlin"},{"issue":"2","key":"1684_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1176\/appi.ajp.22010071","volume":"180","author":"DA Hien","year":"2023","unstructured":"Hien\u00a0DA, Morgan-L\u00f3pez\u00a0AA, Saavedra\u00a0LM, Ruglass\u00a0LM, Ye\u00a0A, L\u00f3pez-Castro\u00a0T, Fitzpatrick\u00a0S, Killeen\u00a0TK, Norman\u00a0SB, Ebrahimi\u00a0CT, Back\u00a0SE (2023) Project harmony: a\u00a0meta-analysis with individual patient data on behavioral and pharmacologic trials for comorbid posttraumatic stress and alcohol or other drug use disorders. Am J Psychiatry 180(2):155\u2013166. https:\/\/doi.org\/10.1176\/appi.ajp.22010071","journal-title":"Am J Psychiatry"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-024-01684-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-024-01684-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:02:33Z","timestamp":1725534153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-024-01684-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":70,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s00115-024-01684-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"type":"print","value":"0028-2804"},{"type":"electronic","value":"1433-0407"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"14 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Roepke erhielt Verg\u00fctung f\u00fcr die T\u00e4tigkeit im Advisory Board von Boehringer Ingelheim, Bionorica SE, Janssen und Otsuka sowie F\u00f6rderung durch die Deutsche Forschungsgemeinschaft, das Bundesministerium f\u00fcr Bildung und Forschung und den Innovationsfond. Er ist Sponsorvertreter der Studien: EudraCT-Nr. 2021-000319-21 und 2019-002211-25 und war an der retrospektiven Analyse zur Wirksamkeit von Doxazosin bei PTBS und Albtr\u00e4umen beteiligt. J.\u00a0Schellong wird Boehringer Ingelheim, Ingelheim, Deutschland im Jahr 2024 beraten. U.\u00a0Schmidt ist Beraterin von Boehringer Ingelheim, Ingelheim, Deutschland, h\u00e4lt Vortr\u00e4ge f\u00fcr Johnson & Johnson (vormals Jansen Pharma)  und hat ein Patent f\u00fcr das anxiolytische Neuropeptid S angemeldet. N.\u00a0Bergemann und U.\u00a0Frommberger geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}